SCHEMBL4156620

SCHEMBL4156620

Cc1ccccc(O)c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 2/20 0.50
ATM Q13315 2/20 0.50
CXCR2 P25025 1/20 0.47
DBH P09172 2/20 0.46
MMP2 P08253 1/20 0.46
ALDH1A1 P00352 4/20 0.45
LMNA P02545 3/20 0.45
HSD17B10 Q99714 3/20 0.45
KDM4E B2RXH2 2/20 0.45
HPGD P15428 2/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
TSHR P16473 2/20 0.45
MAPT P10636 2/20 0.45
CA12 O43570 1/20 0.45
GMNN O75496 1/20 0.45
EGFR P00533 1/20 0.45
CA2 P00918 1/20 0.45
FYN P06241 1/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Orthocresol SCHEMBL28292682 0.80
SCHEMBL122963 0.80 ALDH1A1 (0.60) DBHMMP2ALDH1A1LMNAHSD17B10
Orthocresol SCHEMBL170162 0.77 TRPA1 (0.60) TRPA1ATMALDH1A1LMNAHSD17B10
Orthocresol SCHEMBL8710164 0.77 TRPA1 (0.60) TRPA1ATMALDH1A1LMNAHSD17B10
Orthocresol SCHEMBL10419161 0.77 TRPA1 (0.60) TRPA1ATMALDH1A1LMNAHSD17B10
Orthocresol SCHEMBL16002 0.77
Orthocresol SCHEMBL29395276 0.77
Orthocresol SCHEMBL27388034 0.76 TRPA1 (0.52) TRPA1ATMCXCR2DBHMMP2
Orthocresol SCHEMBL300420 0.76 TRPA1 (0.52) TRPA1ATMCXCR2DBHMMP2
Orthocresol SCHEMBL9764178 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0267378-B1 TROPOLONE DERIVATIVES AS AN ANTI-MYCOPLASMA AGENT SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) 1992-11-04 EP claimed
EP-0267378-A2 Tropolone derivatives as an anti-mycoplasma agent SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) 1988-05-18 EP claimed
US-9790158-B2 Substituted tropolone derivatives and methods of use UNIVERSITY OF CONNECTICUT (US) 2017-10-17 US disclosed
US-20150166448-A1 Substituted Tropolone Derivatives and Methods of Use UNIVERSITY OF CONNECTICUT 2015-06-18 US disclosed
US-20090081134-A1 Oral Care Compositions Comprising Tropolone Compounds and Essential Oils and Methods of Using The Same PAN PAULINE 2009-03-26 US disclosed
EP-1536759-A1 ORAL CARE COMPOSITION COMPRISING TROPOLONE COMPOUNDS AND ESSENTIAL OILS Warner-Lambert Company LLC (US) 2005-06-08 EP disclosed
US-20040185010-A1 Oral care compositions comprising tropolone compounds and essential oils and methods of using the same MCNEIL-PPC, INC 2004-09-23 US disclosed
WO-2004012692-A1 ORAL CARE COMPOSITION COMPRISING TROPOLONE COMPOUNDS AND ESSENTIAL OILS WARNER-LAMBERT COMPANY LLC (US) 2004-02-12 WO disclosed
US-6689342-B1 DENTISTRY WARNER-LAMBERT COMPANY 2004-02-10 US disclosed
US-20040018154-A1 ORAL CARE COMPOSITIONS COMPRISING TROPOLONE COMPOUNDS AND ESSENTIAL OILS AND METHODS OF USING THE SAME MCNEIL-PPC, INC 2004-01-29 US disclosed
CN-1061655-C Method of manufacturing the cycloheptimidazole derivatives KOTOBUKI SEIYAKU CO LTD (JP) 2001-02-07 CN disclosed
CN-1127752-A Method of manufacturing the cycloheptimidazole derivatives KOTOBUKI SEIYAKU CO LTD (JP) 1996-07-31 CN disclosed
US-5409947-A Treating hypertension, congestive heart failure KOTOBUKI SEIYAKU CO., LTD. (JP) 1995-04-25 US disclosed
EP-0267378-B1 TROPOLONE DERIVATIVES AS AN ANTI-MYCOPLASMA AGENT SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) 1992-11-04 EP disclosed
US-4950686-A Anti-mycoplasma agent SHIONOGI & CO., LTD. (JP) 1990-08-21 US disclosed
EP-0267378-A2 Tropolone derivatives as an anti-mycoplasma agent SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) 1988-05-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090081134-A1 Oral Care Compositions Comprising Tropolone Compounds and Essential Oils and Methods of Using The Same TMSB10, PIGS, TPM3 TRPA1 523/4885ATM 3674/4885CXCR2 3251/4885
US-20040185010-A1 Oral care compositions comprising tropolone compounds and essential oils and methods of using the same TMSB10, PIGS, TPM3 TRPA1 523/4885ATM 3674/4885CXCR2 3251/4885
US-20150166448-A1 Substituted Tropolone Derivatives and Methods of Use HDAC5, HDAC4, HDAC7 TRPA1 4546/4885ATM 2741/4885CXCR2 4220/4885
US-20040018154-A1 ORAL CARE COMPOSITIONS COMPRISING TROPOLONE COMPOUNDS AND ESSENTIAL OILS AND METHODS OF USING THE SAME TMSB10, PIGS, TPM3 TRPA1 523/4885ATM 3674/4885CXCR2 3251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.